Stockreport

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. Class A  (AEON) 
PDF – Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosi [Read more]